Cystic Fibrosis

Bronchiectasis

All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.
Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.

Comprehensive Respiratory Physiotherapy

Bezmialem Vakif Universitesi, Department of Physiotherapy and Rehabilitation

Comparison of the Efficacy of Comprehensive Respiratory Physiotherapy in Children With Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis

FVC will be measured using basic spirometry and expressed as the percentage of the predicted value according to the guideline of European Respiratory Society (ERS)

FEV1 will be measured using basic spirometry and expressed as the percentage of the predicted value according to the guideline of European Respiratory Society (ERS)

PEF will be measured using basic spirometry and expressed as the percentage of the predicted value according to the guideline of European Respiratory Society (ERS)

Maximum Inspiratory Pressure (MIP) will be measured using MicroRPM portable manometer and the unit will be expressed in mmHg

Maximum Expiratory Pressure (MEP) will be measured using MicroRPM portable manometer and the unit will be expressed in mmHg

Distance walked in six minutes will be recorded in meters. Test will be conducted according to the guideline of American Thoracic Society (ATS)

sometric M. Quadriceps strength (kg) will be measured using electronic hand held dynamometer in sitting position.

Bezmialem Vakif University

Basal Proteinuria in Pregnancy

Zekai Tahir Burak Maternity Hospital

Association Between Basal Proteinuria Levels and Pregnancy Outcomes in Familial Mediterranean Fever

cantekin iskender

Perinatology

Zekai Tahir Burak Women's Health Research and Education Hospital

•Patients randomized to placebo will receive syringes identical to active drug (100 mg prefilled syringes for subcutaneous injection) filled with drug vehicle

Patients randomized to active drug will receive Kineret (Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.

Familial Mediterranean Fever

Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.

Kineret

Sheba Medical Center

Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever

A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever

Total number of FMF attacks in abdominal, thoracic, skin or joint locations during the observational period (4 months) as recorded in the patient diary, devided by 4 for each patient will result in number of attacks per one month. The number of patients with less than 1 attack per month will be compared between the 2 study groups

Secondary endpoint is defined as total number of serious adverse events per 4 months in each study group. SAE is defined as an adverse event that meets one or more of the following criteria/outcomes:
Death
Life-threatening (i.e., at immediate risk of death)
In-patient hospitalization or prolongation of existing hospitalization
Persistent or significant disability/incapacity
Congenital anomaly/birth defect

Prof.Avi Livneh

Principal Investigator, Head of Internal Medicine "F" , Director of national center of FMF, Israel

1.Fulfilling the Tel Hashomer criteria for the diagnosis of FMF [5].
2.Suffering from episodes of exertional leg pain and or exertional ankle edema
3.18-45 years old
4.On a stable (≥ 2 weeks) dose of oral colchicine therapy
5.Non-smokers

Control group
1.Healthy subjects
2.18-45 years old
3.Non-smokers

pleurisy/febră

Comparison of the Efficacy of Comprehensive Respiratory Physiotherapy in Children With Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis

Association Between Basal Proteinuria Levels and Pregnancy Outcomes in Familial Mediterranean Fever

Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever

Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients

Cea mai completă bază de date cu plante medicinale susținută de știință